Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inotek Pharmaceuticals CorpfiledCriticalInotek Pharmaceuticals Corp
Publication of NZ700629ApublicationCriticalpatent/NZ700629A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
The present disclosure is directed to a combination or a kit comprising a prostaglandin analog and an adenosine receptor A1 agonist of formula (I) and to a method of reducing intraocular pressure (IOP) in a subject using such combination or kit. The disclosire is particularly directed to a combination of latanoprost marketed under the brand Xalatan TM and Compound A.
NZ700629A2010-01-112011-01-11Combination, kit and method of reducing intraocular pressure
NZ700629A
(en)
7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)- cyclopentyl]-n-ethyl-hept-5-enamide (bimatoprost) in crystalline form ii, methods for preparation, and methods for use thereof.